Lupa Kata Sandi? Klik di Sini

atau Masuk melalui

Belum Memiliki Akun Daftar di Sini


atau Daftar melalui

Sudah Memiliki Akun Masuk di Sini

Konfirmasi Email

Kami telah mengirimkan link aktivasi melalui email ke rudihamdani@gmail.com.

Klik link aktivasi dan dapatkan akses membaca 2 artikel gratis non Laput di koran dan Majalah Tempo

Jika Anda tidak menerima email,
Kirimkan Lagi Sekarang

BPOM Approves Ivermectin as Covid-19 Therapeutic Drug

15 July 2021 08:07 WIB

Ivermectin. shutterstock.com

TEMPO.CO, JakartaThe Indonesian Food and Drug Monitoring Agency or BPOM has finally granted the Emergency Use Authorization for anti-parasitic drug ivermectin as the therapeutic drug to support the Covid-19 treatment.

The approval was stipulated in the agency’s Circular concerning the distribution of drugs with an emergency use permit. 

Based on the copy of the circular received by Bisnis.com from the special staffer of the SOE Minister, Arya Sinulingga, on Wednesday evening, July 14, the agency head decided to allow the use of eight drugs for Covid-19 treatment.

The Circular was inked by the BPOM head No. HK.02.02.1.2.07.21.281 of 2021 on the second amendment to the BPOM Decree No. HK.02.02.1.2.11.20.1126 of 2020.

Besides ivermectin, the circular noted seven other therapeutic drugs for Covid-19 treatment, viz. Remdesivir, Favipiravir, Oseltamivir, Immunoglobulin, Ivermectin, Tocilizumab, Azithromycin, and Dexamethasone.

Read also: Hopes and Fears for Ivermectin

BISNIS.COM



COVID-19 Journey and Future Pandemics

1 hari lalu

COVID-19 Journey and Future Pandemics

COVID-19 pandemic has changed people's lives in many aspects. Global citizens are expected to learn the lesson and be prepared for future pandemics.


Pneumonia Cases Rise During Rainy Season; Jakartans Urged to Take Extra Care

1 hari lalu

Pneumonia Cases Rise During Rainy Season; Jakartans Urged to Take Extra Care

The Jakarta Health Agency called on residents to be cautious of catching diseases during the transition from the dry season to the rainy season.


Ex-Covid 19 Task Force Head Doni Monardo Passes Away at 60

1 hari lalu

Ex-Covid 19 Task Force Head Doni Monardo Passes Away at 60

Former head of the Covid-19 Acceleration Handling Task Force, Lieutenant General TNI (Ret.) Doni Monardo, passed away on Sunday, December 3, 2023.


China's Respiratory Illness Rise Due to Known Pathogens, Official Says

2 hari lalu

China's Respiratory Illness Rise Due to Known Pathogens, Official Says

China's surge in respiratory illness is caused by known pathogens and there is no sign of new infectious diseases, a health official says on Saturday.


Experts Urge COVID-19 Treatment in the Endemic Age

15 hari lalu

Experts Urge COVID-19 Treatment in the Endemic Age

COVID-19 treatment is important to be done early to prevent severe illness or even inflammation which will need different treatments.


2023 APSR: Covid-19 Still Poses Health Risks

16 hari lalu

2023 APSR: Covid-19 Still Poses Health Risks

Despite its endemic status, people are still expected to remain aware of COVID-19 as it may pose severe health risks.


Health Minister: 'Monkeypox Won't Spread as Fast as COVID-19'

21 hari lalu

Health Minister: 'Monkeypox Won't Spread as Fast as COVID-19'

Indonesian Health Minister Budi Gunadi Sadikin called on the public to remain calm amid the rising number of monkeypox or mpox cases in the country.


Trade Ministry Mulls Kratom Export with National Narcotics Agency

1 September 2023

Trade Ministry Mulls Kratom Export with National Narcotics Agency

The Trade Ministry will discuss kratom export with BNN and BPOM


Indonesian Govt to Cease Covid-19 Funding

22 Agustus 2023

Indonesian Govt to Cease Covid-19 Funding

The government of Indonesia has stopped the special funding for Covid-19 patients.


Indonesia Ready to Tackle New COVID-19 Variant Eris, Says Minister Muhadjir

8 Agustus 2023

Indonesia Ready to Tackle New COVID-19 Variant Eris, Says Minister Muhadjir

The latest variant of COVID-19, EG.5.1 or dubbed Eris, recently caused a surge in cases in the UK.